27  July 2009

Statement by Elder Pharmaceuticals Limited ("Elder") regarding Neutrahealth plc ("Neutrahealth")

On 26 March 2009, Elder announced that it was still considering its options with regard to its investment in Neutrahealth, which may or may not involve an offer for Neutrahealth. Elder has reviewed its options and confirms that it has no intention of making an offer for Neutrahealth at this time.

 
Under Rule 2.8 of the City Code on Takeovers and Mergers, and except with the consent of the Panel, the statement in the preceding paragraph will prevent Elder or anyone acting in concert with it from announcing an offer or possible offer for Neutrahealth or taking certain other action within the next six months unless there has occurred an event which is specified as enabling the statement to be set aside. Accordingly, for the purposes of Rule 2.8 of the City Code, Elder reserves the right (on behalf of itself and anyone acting in concert with it) to announce an offer or possible offer for Neutrahealth and/or to take any other action which would otherwise be restricted under Rule 2.8 of the City Code within the next six months in the event that: 

(i) the agreement or recommendation of the Board of Neutrahealth is forthcoming;  

(ii) a third party announces an offer or possible offer for Neutrahealth; 

(iii) Neutrahealth announces a 'whitewash proposal' or a 'reverse takeover' (each as defined in the Takeover Code); or

(iv) there is a material change in circumstances.

Enquiries:

Jagdish Saxena (Managing Director)

Elder Pharmaceuticals Limited

00 91 22 2673 0058

David McCorquodale

KPMG Corporate Finance

020 7311 1000

RNS news service provided by Hemscott Group Limited.